This page shows you your search results in order of date. This is page number 14.
Order by Relevance | Date
Total 17126 results found since Jan 2013.
Non-scarring alopecia of lupus erythematosus: A comprehensive review
DISCUSSION: Diffuse/patchy NSA and lupus hair may represent a topographic variation of a single entity specific for LE. Prospective studies are warranted to further document the clinical significance of this manifestation.PMID:37598015 | DOI:10.1016/j.annder.2023.04.002
Source: Annales de Dermatologie et de Venereologie - August 19, 2023 Category: Dermatology Authors: A Perales D Lipsker B Cribier C Lenormand Source Type: research
Investigation of Oral Finasteride Enhanced Occipital Hair Diameter Index in Different Types of Male Androgenetic Alopecia
Source: Journal of the American Academy of Dermatology - August 19, 2023 Category: Dermatology Authors: Qin Wang, Kai Yang, Juiming Lin, Qingmei Liu, Yifei Zhu, Zheng Li, Chunya Ni, Jinran Lin, Wenyu Wu Source Type: research
Alopecia Universalis in an Elderly Chinese Man Induced by Sacubitril/Alisartan, a Novel Angiotensin Receptor-Neprilysin Inhibitor
Source: Journal of Inflammation Research - August 18, 2023 Category: Allergy & Immunology Tags: Journal of Inflammation Research Source Type: research
Scalp Infection Caused by Mycobacterium abscessus Manifested as Patchy Alopecia in an Immunocompetent Female
Source: Infection and Drug Resistance - August 18, 2023 Category: Infectious Diseases Tags: Infection and Drug Resistance Source Type: research
A New Treatment Option for a Form of Sudden Hair Loss
THURSDAY, Aug. 17, 2023 -- A new type of medication, JAK inhibitors, can effectively treat moderate to severe alopecia areata, a hair loss condition that has been historically hard to treat.
A study of its effectiveness, by Dr. Brett King and Dr....
Source: Drugs.com - Daily MedNews - August 17, 2023 Category: General Medicine Source Type: news
Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice
Ann Dermatol Venereol. 2023 Aug 14:S0151-9638(23)00047-9. doi: 10.1016/j.annder.2022.11.013. Online ahead of print.ABSTRACTCyclin-dependent kinase (CDK) 4/6 inhibitors (palbociclib, ribociclib and abemaciclib) have revolutionized the treatment of metastatic breast carcinoma. They currently form the first-line treatment, in combination with endocrine agents, for the management of locally advanced or metastatic hormone receptor-positive (HR + ), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, the largest subtype of breast carcinoma. CDK 4/6 inhibitors have shown comparable efficacy outcomes with pred...
Source: Annales de Dermatologie et de Venereologie - August 16, 2023 Category: Dermatology Authors: V Sibaud P Sollena Source Type: research
